EP3600452A1 - Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer - Google Patents
Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancerInfo
- Publication number
- EP3600452A1 EP3600452A1 EP18775715.8A EP18775715A EP3600452A1 EP 3600452 A1 EP3600452 A1 EP 3600452A1 EP 18775715 A EP18775715 A EP 18775715A EP 3600452 A1 EP3600452 A1 EP 3600452A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- och
- groups
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 80
- 201000011510 cancer Diseases 0.000 title claims description 73
- 238000001959 radiotherapy Methods 0.000 title claims description 6
- 150000002678 macrocyclic compounds Chemical class 0.000 title description 13
- 239000000203 mixture Substances 0.000 claims abstract description 130
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 125000003118 aryl group Chemical group 0.000 claims description 96
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- 230000008685 targeting Effects 0.000 claims description 59
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- 229910052757 nitrogen Inorganic materials 0.000 claims description 45
- 229910052799 carbon Inorganic materials 0.000 claims description 43
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 31
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000002837 carbocyclic group Chemical group 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010038807 Oligopeptides Proteins 0.000 claims description 5
- 102000015636 Oligopeptides Human genes 0.000 claims description 5
- 229960005562 radium-223 Drugs 0.000 claims description 5
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical group [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 claims description 4
- 229940125666 actinium-225 Drugs 0.000 claims description 4
- RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 claims description 4
- RYXHOMYVWAEKHL-RKEGKUSMSA-N astatine-217 Chemical compound [217At] RYXHOMYVWAEKHL-RKEGKUSMSA-N 0.000 claims description 4
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims description 4
- MIORUQGGZCBUGO-YPZZEJLDSA-N fermium-255 Chemical compound [255Fm] MIORUQGGZCBUGO-YPZZEJLDSA-N 0.000 claims description 4
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 claims description 4
- GZCRRIHWUXGPOV-CBESVEIWSA-N terbium-149 Chemical compound [149Tb] GZCRRIHWUXGPOV-CBESVEIWSA-N 0.000 claims description 4
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 claims description 4
- JFALSRSLKYAFGM-QQVBLGSISA-N uranium-230 Chemical compound [230U] JFALSRSLKYAFGM-QQVBLGSISA-N 0.000 claims description 4
- ZSLUVFAKFWKJRC-VENIDDJXSA-N thorium-226 Chemical compound [226Th] ZSLUVFAKFWKJRC-VENIDDJXSA-N 0.000 claims description 3
- 125000003700 epoxy group Chemical group 0.000 claims 13
- 238000005516 engineering process Methods 0.000 abstract description 59
- 150000001875 compounds Chemical class 0.000 abstract description 55
- 238000011282 treatment Methods 0.000 abstract description 6
- 125000000524 functional group Chemical group 0.000 description 75
- -1 alkenoxy Chemical group 0.000 description 67
- 239000000243 solution Substances 0.000 description 60
- 235000002639 sodium chloride Nutrition 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 39
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 31
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 229910001868 water Inorganic materials 0.000 description 27
- 125000004093 cyano group Chemical group *C#N 0.000 description 23
- 239000000725 suspension Substances 0.000 description 23
- 150000002118 epoxides Chemical group 0.000 description 22
- 150000001721 carbon Chemical group 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 239000003446 ligand Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- PKCFWCMMZOUICG-UHFFFAOYSA-N 6-[[16-[(6-carboxypyridin-2-yl)methyl]-1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-yl]methyl]-4-isothiocyanatopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(CN2CCOCCOCCN(CC3=NC(=CC(=C3)N=C=S)C(O)=O)CCOCCOCC2)=N1 PKCFWCMMZOUICG-UHFFFAOYSA-N 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000011550 stock solution Substances 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000000163 radioactive labelling Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 238000010668 complexation reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000004293 19F NMR spectroscopy Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229910002249 LaCl3 Inorganic materials 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910052765 Lutetium Inorganic materials 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- SNGPHFVJWBKEDG-UHFFFAOYSA-N 4-oxo-1h-pyridine-2,6-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CC(=O)C=C(C(O)=O)N1 SNGPHFVJWBKEDG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 238000010887 ISOL method Methods 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 208000033749 Small cell carcinoma of the bladder Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- MGTKGBOTKLXIMO-UHFFFAOYSA-N dimethyl 4-azidopyridine-2,6-dicarboxylate Chemical compound COC(=O)C1=CC(N=[N+]=[N-])=CC(C(=O)OC)=N1 MGTKGBOTKLXIMO-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052746 lanthanum Inorganic materials 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- AEDROEGYZIARPU-UHFFFAOYSA-K lutetium(iii) chloride Chemical compound Cl[Lu](Cl)Cl AEDROEGYZIARPU-UHFFFAOYSA-K 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229940081066 picolinic acid Drugs 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000004763 sulfides Chemical class 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000006478 transmetalation reaction Methods 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 201000007710 urinary bladder small cell neuroendocrine carcinoma Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 150000007549 18-membered macrocycles Chemical class 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000463291 Elga Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MZTSUWWTESDXNW-UHFFFAOYSA-N dimethyl 4-aminopyridine-2,6-dicarboxylate Chemical compound COC(=O)C1=CC(N)=CC(C(=O)OC)=N1 MZTSUWWTESDXNW-UHFFFAOYSA-N 0.000 description 1
- NFXKYKHKNUFOKB-UHFFFAOYSA-N dimethyl 4-chloropyridine-2,6-dicarboxylate Chemical compound COC(=O)C1=CC(Cl)=CC(C(=O)OC)=N1 NFXKYKHKNUFOKB-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- HQWGIAKLCKBMQN-UHFFFAOYSA-N ethyl 4-amino-6-(chloromethyl)pyridine-2-carboxylate Chemical compound NC1=CC(=NC(=C1)CCl)C(=O)OCC HQWGIAKLCKBMQN-UHFFFAOYSA-N 0.000 description 1
- BDYPXQLOPSQEBR-UHFFFAOYSA-N ethyl 4-amino-6-(hydroxymethyl)pyridine-2-carboxylate Chemical compound NC1=CC(=NC(=C1)CO)C(=O)OCC BDYPXQLOPSQEBR-UHFFFAOYSA-N 0.000 description 1
- NXIKTSBSIRKUDI-UHFFFAOYSA-N ethyl 4-amino-6-[[16-[(6-methoxycarbonylpyridin-2-yl)methyl]-1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-yl]methyl]pyridine-2-carboxylate Chemical compound NC1=CC(=NC(=C1)CN1CCOCCOCCN(CCOCCOCC1)CC1=NC(=CC=C1)C(=O)OC)C(=O)OCC NXIKTSBSIRKUDI-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000192 extended X-ray absorption fine structure spectroscopy Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 229910052730 francium Inorganic materials 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 238000001730 gamma-ray spectroscopy Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- HCUXDHNQNACWQF-UHFFFAOYSA-N methyl 6-(1,4,10,13-tetraoxa-7,16-diazacyclooctadec-7-ylmethyl)pyridine-2-carboxylate Chemical compound O1CCOCCN(CCOCCOCCNCC1)CC1=CC=CC(=N1)C(=O)OC HCUXDHNQNACWQF-UHFFFAOYSA-N 0.000 description 1
- GJPCYWXDNLDHAT-UHFFFAOYSA-N methyl 6-(chloromethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(CCl)=N1 GJPCYWXDNLDHAT-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 238000002727 particle therapy Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 125000003367 polycyclic group Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940051022 radioimmunoconjugate Drugs 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- ZSLUVFAKFWKJRC-UHFFFAOYSA-N thorium Chemical compound [Th] ZSLUVFAKFWKJRC-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the present technology generally relates to macrocyclic complexes of alpha-emitting radionuclides, as well as compositions including such compounds and methods of use.
- a 1 represents a nitrogen atom (N) or CR 1
- a 2 represents a nitrogen atom (N) or CR 2
- a 3 represents a nitrogen atom (N) or CR 3
- a 4 represents a nitrogen atom (N) or CR 4
- a 5 represents a nitrogen atom (N) or CR 5
- a 6 represents a nitrogen atom (N) or CR 6
- a 7 represents a nitrogen atom (N)
- A represents a nitrogen atom (N) or CR ;
- A represents a nitrogen atom (N) or CR ;
- a 10 represents a nitrogen atom (N) or CR 10 ; provided that no more than three of A 1 , A 2 , A 3 , A 4 , and A 5 can be nitrogen atoms, and no more than three of A 6 , A 7 , A 8 , A 9 , and A 10 can be nitrogen atoms;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are each independently selected from H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halo, -OR', - (OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10),
- R' is independently at each occurance H, Ci-C 6 alkyl, C3-C6 cycloalkyl, C 2 -C 6 alkenyl, C5-C5 cycloalkenyl, C 2 -C 6 alkynyl, C5-C6 aryl, heterocyclyl, or heteroaryl, or wherein two R' groups attached to the same atom are interconnected to form a three- to six-membered ring.
- the groups L 1 and L 2 in Formula (I) are linkers independently selected from -(CH 2 ) P -, where p is a value of 1, 2, or 3.
- the subscripts r and s in Formula (I) are independently 0 or 1. When r is 0 or when s is 0, then L 1 or L 2 , respectively, is not present, which results in a direct bond between the respective aromatic ring and the macrocycle.
- a targeting composition is provided that is represented by Formula (II)
- a ⁇ A 10 , M, L 1 , L 2 , r, and s have the same meanings provided provided for any embodiment herein with the exception that at least one of R ⁇ -R 10 is or includes a selective cancer cell targeting group.
- compositions e.g.
- compositions and medicaments comprising any of one of the embodiments of the compounds of Formula II (or a pharmaceutically acceptable salt thereof) disclosed herein and a pharmaceutically acceptable carrier or one or more excipients or fillers.
- the present technology provides a method of treating cancer by administering an effective amount of the targeting composition according to Formula (II) to a subject having cancer.
- FIGs. 1 A and IB shows x-ray crystal structures of [La(Hmacropa)(H 2 0)] (C104) 2 (FIG. 1 A, side view; FIG. 2B, top view).
- FIGs. 1C and ID shows x-ray crystal structures of
- FIGs. 2A-C shows the biodistribution of 225 Ac(N0 3 ) 3 (FIG. 2A), [ 225 Ac(macropa)] + (FIG. 2B), and [ 225 Ac(DOTA)]- (FIG. 2C) for select organs following intravenous injection in mice.
- Adult C57BL/6 mice were sacrificed 15 min, 1 h, or 5 h post injection. Values for each time point are given as mean % ID/g ⁇ 1 SD.
- references to a certain element such as hydrogen or H is meant to include all isotopes of that element.
- an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
- Compounds comprising radioisotopes such as tritium, C 14 , P 32 and S 35 are thus within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.
- substituted refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms.
- Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
- a substituted group is substituted with one or more substituents, unless otherwise specified.
- a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents.
- substituent groups include: halogens (i.e., F, CI, Br, and I); hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo);
- carboxylates esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF 5 ), sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
- C m -C n such as C 1 -C 12 , Ci-C 8 , or Ci-C 6 when used before a group refers to that group containing m to n carbon atoms.
- Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
- straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
- branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
- Alkyl groups may be substituted or unsubstituted. Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above, and include without limitation haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.
- Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms.
- Exemplary monocyclic cycloalkyl groups include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
- the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7.
- Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like.
- Cycloalkyl groups may be substituted or unsubstituted. Substituted cycloalkyl groups may be substituted one or more times with, non-hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
- Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
- Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.
- cycloalkylalkyl groups have from 4 to 16 carbon atoms, 4 to 12 carbon atoms, and typically 4 to 10 carbon atoms.
- Cycloalkylalkyl groups may be substituted or unsubstituted. Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl or both the alkyl and cycloalkyl portions of the group.
- Representative substituted cycloalkylalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Alkenyl groups may be substituted or unsubstituted. Representative substituted alkenyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Cycloalkenyl groups include cycloalkyl groups as defined above, having at least one double bond between two carbon atoms. Cycloalkenyl groups may be substituted or
- the cycloalkenyl group may have one, two or three double bonds but does not include aromatic compounds.
- Cycloalkenyl groups have from 4 to 14 carbon atoms, or, in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.
- Cycloalkenylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Cycloalkenylalkyl groups may be substituted or unsubstituted. Substituted cycloalkenylalkyl groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Alkynyl groups include straight and branched chain alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms.
- Alkynyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
- the alkynyl group has one, two, or three carbon-carbon triple bonds. Examples include, but are not limited to -C ⁇ CH, -C ⁇ CCH 3 , -CH 2 C ⁇ CCH 3 , -C ⁇ CCH 2 CH(CH 2 CH 3 ) 2 , among others.
- Alkynyl groups may be substituted or unsubstituted.
- Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
- Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems.
- aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups.
- aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups. In some embodiments, the aryl groups are phenyl or naphthyl. Aryl groups may be substituted or unsubstituted.
- aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl,
- substituted aryl groups may be mono- substituted or substituted more than once.
- monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.
- Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
- aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms.
- Aralkyl groups may be substituted or unsubstituted. Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group.
- Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl.
- Representative substituted aralkyl groups may be substituted one or more times with substituents such as those listed above.
- Heterocyclyl groups include aromatic (also referred to as heteroaryl) and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S.
- the heterocyclyl group contains 1, 2, 3 or 4 heteroatoms.
- heterocyclyl groups include mono-, bi- and tricyclic rings having 3 to 16 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 14 ring members.
- Heterocyclyl groups encompass aromatic, partially unsaturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups.
- heterocyclyl group includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3- dihydrobenzo[l,4]dioxinyl, and benzo[l,3]dioxolyl.
- the phrase also includes bridged poly cyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
- Heterocyclyl groups may be substituted or unsubstituted.
- Heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pipendyl, piperazinyl, morpholinyl, thiomorpholinyl, t
- substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.
- Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
- Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl,
- benzothiophenyl furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl, imidazopyridinyl (azabenzimidazolyl), pyrazolopyridinyl, triazolopyridinyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl,
- Heteroaryl groups include fused ring compounds in which all rings are aromatic such as indolyl groups and include fused ring compounds in which only one of the rings is aromatic, such as 2,3-dihydro indolyl groups. Heteroaryl groups may be substituted or unsubstituted.
- heteroaryl groups includes fused ring compounds as well as includes heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above.
- Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Heterocyclylalkyl groups may be substituted or unsubstituted. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and heterocyclyl portions of the group.
- heterocyclyl alkyl groups include, but are not limited to, morpholin-4-yl-ethyl, furan-2-yl-methyl, imidazol-4-yl-methyl, pyridin-3-yl-methyl, tetrahydrofuran-2-yl-ethyl, and indol-2-yl-propyl.
- Representative substituted heterocyclylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Heteroaralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.
- Heteroaralkyl groups may be substituted or unsubstituted. Substituted heteroaralkyl groups may be substituted at the alkyl, the heteroaryl or both the alkyl and heteroaryl portions of the group. Representative substituted heteroaralkyl groups may be substituted one or more times with substituents such as those listed above.
- Groups described herein having two or more points of attachment i.e., divalent, trivalent, or polyvalent
- divalent alkyl groups are alkylene groups
- divalent aryl groups are arylene groups
- divalent heteroaryl groups are divalent heteroarylene groups, and so forth.
- Substituted groups having a single point of attachment to the compound of the present technology are not referred to using the "ene" designation.
- chloroethyl is not referred to herein as chloroethyl ene.
- Such groups may further be substituted or unsubstituted.
- Alkoxy groups are hydroxyl groups (-OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above.
- linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like.
- branched alkoxy groups include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like.
- Examples of cycloalkoxy groups include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
- Alkoxy groups may be substituted or
- substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
- alkanoyl and “alkanoyloxy” as used herein can refer, respectively, to - C(0)-alkyl and -0-C(0)-alkyl groups, where in some embodiments the alkanoyl or alkanoyloxy groups each contain 2-5 carbon atoms.
- aryloyl and
- aryloyloxy respectively refer to -C(0)-aryl and -0-C(0)-aryl groups.
- aryloxy and arylalkoxy refer to, respectively, a substituted or unsubstituted aryl group bonded to an oxygen atom and a substituted or unsubstituted aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy groups may be substituted one or more times with substituents such as those listed above.
- carboxylic acid refers to a compound with a -C(0)OH group.
- carboxylate refers to a -C(0)0 ⁇ group.
- a “protected carboxylate” refers to a -C(0)0-G where G is a carboxylate protecting group.
- Carboxylate protecting groups are well known to one of ordinary skill in the art. An extensive list of protecting groups for the carboxylate group functionality may be found in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999) which can be added or removed using the procedures set forth therein and which is hereby incorporated by reference in its entirety and for any and all purposes as if fully set forth herein.
- esters refers to -COOR 70 groups.
- R 70 is a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- amide (or “amido”) includes C- and N-amide groups, i.e., -C(0)NR 71 R 72 ,
- R and R are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- Amido groups therefore include but are not limited to carbamoyl groups (-C(0)NH 2 ) and formamide groups (-NHC(O)H).
- the amide is -NR 71 C(0)-(Ci -5 alkyl) and the group is termed "carbonylamino," and in others the amide is -NHC(0)-alkyl and the group is termed "alkanoylamino.”
- nitrile or "cyano” as used herein refers to the -CN group.
- Urethane groups include N- and O-urethane groups, i.e., -NR 73 C(0)OR 74 and
- R and R are independently a substituted or
- R 73 may also be H.
- amine refers to -NR 75 R 76 groups, wherein R 75 and R 76 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- the amine is alkylamino, dialkylamino, arylamino, or alkylarylamino.
- the amine is H 2 , methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
- sulfonamido includes S- and N-sulfonamide groups, i.e., -S0 2 R 78 R 79 and
- R and R are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
- Sulfonamido groups therefore include but are not limited to sulfamoyl groups (-S0 2 H 2 ).
- the sulfonamido is - HS0 2 -alkyl and is referred to as the "alkylsulfonylamino" group.
- thiol refers to -SH groups, while sulfides include -SR 80 groups, sulfoxides
- 81 82 83 include -S(0)R groups, sulfones include -S0 2 R groups, and sulfonyls include -S0 2 OR .
- R , R , R , and R * " are each independently a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- the sulfide is an alkylthio group, -S-alkyl.
- urea refers to - R 84 -C(0)- R 85 R 86 groups.
- R 84 , R 85 , and R 86 groups are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.
- amidine refers to -C( R 87 ) R 88 R 89 and - R 87 C( R 88 )R 89 , wherein R 87 , R 88 , and R 89 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- guanidine refers to - R 90 C( R 91 ) R 92 R 93 , wherein R 90 , R 91 , R 92 and R 93 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- halogen refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.
- hydroxyl as used herein can refer to -OH or its ionized form, -O " .
- imide refers to -C(0) R y8 C(0)R , wherein R ys and R yy are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- R 101 are each independently hydrogen or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein, with the proviso that R 100 and R 101 are not both simultaneously hydi
- nitro refers to an -N0 2 group.
- trifluoromethyl refers to -CF 3 .
- trifluoromethoxy refers to -OCF 3 .
- zido refers to -N 3 .
- trialkyl ammonium refers to a -N(alkyl) 3 group.
- a trialkylammonium group is positively charged and thus typically has an associated anion, such as halogen anion.
- trifluoromethyldiazirido refers to .
- isocyano refers to -NC.
- isothiocyano refers to -NCS.
- pentafluorosulfanyl refers to -SF 5 .
- a range includes each individual member.
- a group having 1-3 atoms refers to groups having 1, 2, or 3 atoms.
- a group having 1-5 atoms refers to groups having 1, 2, 3, 4, or 5 atoms, and so forth.
- Pharmaceutically acceptable salts of compounds described herein are within the scope of the present technology and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable).
- pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
- inorganic acids such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid
- organic acids e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, ox
- the compound of the present technology when it has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na , Li , K , Ca , Mg , Zn ), ammonia or organic amines (e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine,
- alkali and earth alkali metals e.g., Na , Li , K , Ca , Mg , Zn
- ammonia or organic amines e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine,
- salts can be prepared in situ during isolation and purification of the compounds or by separately reacting the purified compound in its free base or free acid form with a suitable acid or base, respectively, and isolating the salt thus formed.
- Tautomers refers to isomeric forms of a compound that are in equilibrium with each other. The presence and concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, quinazolinones may exhibit the following isomeric forms, which are referred to as tautomers of each other:
- guanidines may exhibit the following isomeric forms in protic organic solution, also referred to as tautomers of each other:
- Stereoisomers of compounds include all chiral, diastereomeric, and racemic forms of a structure, unless the specific stereochemistry is expressly indicated.
- compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions.
- racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these stereoisomers are all within the scope of the present technology.
- the compounds of the present technology may exist as solvates, especially hydrates. Hydrates may form during manufacture of the compounds or compositions comprising the compounds, or hydrates may form over time due to the hygroscopic nature of the compounds.
- Compounds of the present technology may exist as organic solvates as well, including DMF, ether, and alcohol solvates among others. The identification and preparation of any particular solvate is within the skill of the ordinary artisan of synthetic organic or medicinal chemistry.
- the macrocycles currently in use ⁇ e.g., DOT A
- the macrocycles currently in use ⁇ e.g., DOT A
- DOT A radionuclides of larger size, such as actinium, radium, bismuth, and lead isotopes.
- Such instability results in dissociation of the radionuclide from the macrocycle, and this results in a lack of selectivity to targeted tissue, which also results in toxicity to non-targeted tissue.
- the present technology provides new macrocyclic complexes that are substantially more stable than those of the conventional art.
- these new complexes can advantageously target cancer cells more effectively, with substantially less toxicity to non-targeted tissue than complexes of the art.
- the new complexes can advantageously be produced at room temperature, in contrast to DOTA-type complexes, which generally require elevated
- the present technology also specifically employs alpha-emitting radionuclides instead of beta radionuclides.
- Alpha-emitting radionuclides are of much higher energy, and thus substantially more potent, than beta-emitting radionuclides.
- composition of Formula I is provided:
- M is an alpha-emitting radionuclide
- Exemplary alpha-emitting radionuclides include, but are not limited to, actinium-225 ( 225 Ac 3+ ), radium-223 ( 233 Ra 2+ ), bismuth-213 ( 213 Bi 3+ ), lead-212 ( 212 Pb 2+ and/or 212 Pb 4+ ), terbium-149 ( 149 Tb 3+ ), fermium-255 ( 255 Fm 3+ ), thorium-227 ( 227 Th 4+ ), thorium-226 ( 226 Th 4+ ), astatine-211 ( 211 At + ), astatine-217 ( 217 At + ), and uranium-230.
- a 1 represents a nitrogen atom (N) or CR 1
- a 2 represents a nitrogen atom (N) or CR 2
- a 3 represents a nitrogen atom (N) or CR 3
- a 4 represents a nitrogen atom (N) or CR 4
- a 5 represents a nitrogen atom (N) or CR 5
- a 6 represents a nitrogen atom (N) or CR 6
- a 7 represents a nitrogen atom (N) or CR 7
- a 8 represents a nitrogen atom (N) or CR 8
- a 9 represents a nitrogen atom (N) or CR 9
- a 10 represents a nitrogen atom (N) or CR 10 ; provided that no
- a 6 more than three of A 1 , A 2 , A 3 , A 4 , and A 5 can be nitrogen atoms, and no more than three of A A 7 , A 8 , A 9 , and A 10 can be nitrogen atoms.
- the composition can be symmetric or asymmetric.
- one of the aromatic rings may possess only ring carbon atoms while the other aromatic ring may possess one, two, or three ring nitrogen atoms, or alternatively, for example, one of the aromatic rings may possess a single ring nitrogen atom while the other aromatic ring may possess two or three ring nitrogen atoms.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are each independently selected from H, alkyl, cycloalkyl, alkenyl,
- R' is independently at each occurance H, Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, Cs-C 6 cycloalkenyl, C 2 -C 6 alkynyl, Cs-C 6 aryl, poly(ethylene glycol), heterocyclyl, or heteroaryl, or wherein two R' groups attached to the same atom are
- heteroatom-containing functional groups may function, for example, to modulate the hydrophilicity or hydrophobicity, serve as a reactive functional group (e.g., to bind to a cell targeting agent), or participate in complexing with the radionuclide.
- Some examples of functional groups include alkylnyl, halogen atoms (e.g., F, CI, Br, or I), -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 ) OR' (where ;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', -OC(0)R', - C(0)OR', -C(S)OR', -C(0) R'R', -C(S)NR'R', - R'C(0)R', - R'C(S)R', - R'R', - R'C(0) R', - R'C(S) R', -S(0)R', -S0 2 R', -S0 2 (OR'), -S0 2 R' 2 , -P(0)(OR') 2 , - P(0)R'(OR'),
- the groups L 1 and L 2 in Formula (I) are linkers independently selected from -(CH 2 ) P -, where p is a value of 1, 2, or 3.
- the subscripts r and s in Formula (I) are independently 0 or 1. When r is 0 or when s is 0, then L 1 or L 2 , respectively, is not present, which results in a direct bond between the respective aromatic ring and the macrocycle.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 is a functional group selected from halogen atoms; -OR'; -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10); -(OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR'; - OC(0)R'; -C(0)OR'; -C(S)OR'; -C(0) R'R'; -C(S) R'R'; - R'C(0)R'; - R'C(0)R'; - R'C(0)NR'; -NR'R'; -NR'C(0)NR'; -NR'C(S)NR'; -S(0)R'; -S0 2 R'; -S0 2 (
- R 1 , R 2 , R 3 , R 4 , and R 5 and/or at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is selected from the first set of functional groups. In any embodiment herein, it may be at least one of R 1 , R 2 , R 3 , R 4 , and R 5 and/or at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is selected from the second set of functional groups.
- it may be at least one of R 1 , R 2 , R 3 , R 4 , and R 5 and/or at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is selected from the first set of functional groups, and at least one of R 1 , R 2 , R 3 , R 4 , and R 5 and/or at least one of R 6 , R 7 , R 8 , R 9 , and R 10 is selected from the second set of functional groups.
- a 1 , A 2 , A 3 , A 4 , and A 5 are not nitrogen atoms, and/or A 6 , A 7 , A 8 , A 9 , and A 10 are not nitrogen atoms.
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , and A 10 may all not be nitrogen, where the composition is of Formula I-a
- any embodiment herein it may be at least one of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , and A 10 is a nitrogen atom.
- it may be at least one of A 1 , A 2 , A 3 , A 4 , and A 5 is a nitrogen atom and at least one of A 6 , A 7 , A 8 , A 9 , and A 10 is a nitrogen atom.
- the following sub-generic structures are exemplary of sub-classes of compositions having a single nitrogen atom in each aromatic ring:
- any of the above structures takes at least one of the shown R groups as a functional group, or specifically from the first or second set of functional groups, herein also referred to as "first set functional groups” and "second set functional groups," respectively.
- first set functional groups and “second set functional groups,” respectively.
- R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , and R 10 is not H.
- it may be any of the above structures takes at least one of the shown R groups as a first set functional group and at least one of the shown R groups as a second set functional group.
- it may be any of the above structures takes at least one of the shown R groups as a first set functional group and at least one of the shown R groups as a second set functional group.
- R , R , R , R , R , and R is a first set functional group and at least one
- R R R R R J , R , R°, R', and R iU is a second set functional group. In any embodiment herein, it may be at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a first set functional group.
- R R R R J , R , R°, R', and R iU is a second set functional group. In any embodiment herein, it may be at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a first set functional group.
- At least one of R , R , R , and R and/or at least one of R , R , R , and R may be a first set functional group. In any embodiment herein, it may be at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- at least one of R 2 , R 3 , R 4 , and R 5 and/or at least one of R 7 , R 8 , R 9 , and R 10 may be a second set functional group.
- At least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a first set functional group
- at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- at least one of R 2 , R 3 , R 4 , and R 5 and/or at least one of R 7 , R 8 , R 9 , and R 10 may be a first set functional group
- R , R , R , and R and/or at least one of R , R , R , and R may be a second set functional group.
- it may be that at least two of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , and A 10 are nitrogen atoms.
- it may be that at least two of A 1 , A 2 , A 3 , A 4 , and A 5 are nitrogen atoms and/or at least two of A 6 , A 7 , A 8 , A 9 , and A 10 are nitrogen atoms.
- a 1 , A 2 , A 3 , A 4 , and A 5 are nitrogen atoms and two of A 6 , A 7 , A 8 , A 9 , and A 10 are nitrogen atoms.
- the following sub-generic structures are exemplary of sub-classes of compositions having two nitrogen atoms in each aromatic ring:
- R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , and R 10 can be a first set functional group or a second set functional group.
- R 10 may be any of the above structures takes at least one of the shown R groups as a first set functional group and at least one of the shown R groups as a second set
- R z , R', R", R', R°, and R' may be any one of R z , R', R", R', R°, and R'.
- R z , R', R", R', R°, and R' may be a second set functional group.
- it may be at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a first set functional group.
- R 2 , R 3 , and R 4 and/or at least one of R 7 , R 8 , and R 9 may be a first set functional group.
- it may be at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- R , R , and R and/or at least one of R', R°, and R' may be a second set functional group.
- it may be at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a first set functional group, and at least one of the R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- R groups on one of the aromatic rings and/or at least one of the R groups on the other aromatic ring is a second set functional group.
- Formula (I-e) at least
- R , R , and R and/or at least one of R', R°, and R' may be a first set functional group
- R , R , and R and/or at least one of R', R°, and R' may be a second set functional group.
- An analogous set of examples can be provided for Formula (I-f) by replacing instances of "R 2 , R 3 , and R 4 " with “R 2 , R 4 , and R 5 " and replacing instances of "R 7 , R 8 , and R 9 " with “R 7 , R 9 , and R 10 ".
- any embodiment herein it may be at least three of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , and A 10 in Formula (I) are nitrogen atoms.
- at least three of A 1 , A 2 , A 3 , A 4 , and A 5 are nitrogen atoms and/or at least three of A 6 , A 7 , A 8 , A 9 , and A 10 may be nitrogen atoms.
- the following sub-generic structure is exemplary of a sub-class of compositions having three nitrogen atoms in each aromatic ring:
- At least one of R 2 , R 4 , R 7 , and R 9 may be a first set functional group or a second set functional group.
- Formula (I-g) it may be at least one of R 2 , R 4 , R 7 , and R 9 can be a first set functional group and at least one R 2 , R 4 , R 7 , and R 9 can be a second set functional group. In any embodiment herein of Formula (I-g), it may be at least one of R 2 and R 4 and/or at least one of R 7 and R 9 is a first set functional group. In any embodiment herein of Formula (I-g), it may be at least one of R 2 and R 4 and/or at least one of R 7 and R 9 is a second set functional group.
- R 2 and R 4 and/or at least one of R 7 and R 9 is a first set functional group, and at least one of R 2 and R 4 and/or at least one of R 7 and R 9 is a second set functional group.
- At least one of the A groups in at least one of the aromatic rings in Formula (I) is a carbon atom having a first set functional group appended thereto as an R group.
- at least one of the A groups in each of the aromatic rings is a carbon atom having a first set functional group appended thereto as an R group.
- a 2 and/or A 7 may carbon atoms having a first set functional group appended thereto.
- a 1 and/or A 6 are carbon atoms
- the carbon atoms may have a first set functional group appended thereto.
- the following sub-generic structures are exemplary of some of the above-described compositions:
- the structure may also be asymmetric in the choice of functional group, such as provided in the following exemplary structure:
- At least one of the A groups in at least one of the aromatic rings in Formula (I) is a carbon atom having a second set functional group appended thereto as an R group.
- at least one of the A groups in each of the aromatic rings is a carbon atom having a second set functional group appended thereto as an R group, or only one of the aromatic rings contains at least one second set functional group.
- the second set functional group is a carbon atom having a second set functional group appended thereto as an R group, or only one of the aromatic rings contains at least one second set functional group.
- compositions containing at least one second set functional group are specifically located at A , A , or A , or at A , A or A , or more specifically, at A or A .
- the following sub-generic structures are exemplary of some of the above-described compositions containing at least one second set functional group:
- At least one of the R groups in any of the above structures on the aromatic rings is a first set functional group. In any embodiment herein, it may be that the first set functional group is in the same ring containing the second set functional group.
- any embodiment herein it may be that one or two pairs of directly adjacent groups among R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 groups are interconnected to form a four- to six-membered carbocyclic or nitrogen-containing ring optionally substituted with one or more groups provided above for R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 , wherein the interconnection of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 groups results in a fused ring system that includes the ring shown in Formula (I) containing A 1 , A 2 , A 3 , A 4 , and A 5 , and/or results in a fused ring system that includes the ring shown in Formula (I) containing
- the structures include at least one fused ring system that contains at least one of the shown aromatic rings containing the A groups.
- a sub- generic structure exemplary of such structures is provided as follows:
- a 1 , A 4 , A 5 , A 6 , A 9 , A 10 , L 1 , L 2 , r, s, and M are as provided in any embodiment herein, and R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, halo, -OR', - (OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', -OC(0)R', -C(0)OR', -C(S)OR', -C(0) R'R', -C(S) R'R', - R'C(0)R
- the groups R 15 and R 16 may optionally interconnect to form a second fused ring, which may be the same or different from the first fused ring.
- R 11 , R 12 , R 13 , and R 14 do not further interconnect, which leaves the fused ring as a bicyclic fused ring system; however, in any embodiment herein, it may be that two adjacent groups from among R 11 , R 12 , R 13 , and R 14 can interconnect, thereby forming a tricyclic fused ring system.
- R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 is a group selected from halogen atoms; -OR'; -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10),
- the structures include two fused ring systems that contain each of the shown aromatic rings containing the A groups.
- a sub-generic structure exemplary of such structures is provided as follows:
- a 1 , A 4 , A 5 , A 6 , A 9 , A 10 , L 1 , L 2 , r, s, and M are as defined above, and R 11 , R 12 , R 13 , R 14 , R 17 , R 18 , R 19 , and R 20 are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, halo, -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), - SR', -OC(0)R', -C(0)OR', -C(S)OR', -C(0) R'R', -C(S) R'R', -C(S) R'R',
- any embodiment herein of Formula (I-w) it may be at least one of A 1 , A 4 , A 5 , A 6 , A 9 , and A 10 is a nitrogen atom.
- it may be at least one (i.e., one, two, or all) of A 1 , A 4 , and A 5 is a nitrogen atom and at least one (i.e., one, two, or aallll)) ooff AA 66 ,, AA 99 ,, aanndd AA 1100 is a nitrogen atom.
- a sub-generic structure exemplary of such structures is provided as follows:
- the present technology provides a composition useful in the targeted radiotherapy of cancer.
- the composition targets (i.e., selectively binds to) cancer cells by including in its structure a selective cancer cell targeting group which selectively directs the composition to cancer cells.
- the composition can be conveniently expressed by Formula (I) except that at least one of the R groups includes a selective cancer cell targeting group.
- the selective cancer cell targeting group can be any group known in the art capable of selectively targeting cancer cells.
- the selective cancer cell targeting group may target receptor sites specific to cancer cells.
- the cancer cell targeting group may be composed of amino acids linked by peptide bonds.
- the selective cancer cell targeting group of any embodiment herein may include a cancer-targeting antibody, antibody fragment, a selective targeting oligopeptide containing up to 50 amino acids, an enzyme, a nucleobase-containing moiety (such as an oligonucleotide, DNA or RNA vector, or aptamer), or a lectin.
- any of the foregoing cancer cell targeting agents may be bound or adsorbed onto a particle (e.g., a nanoparticle or microparticle), with the particle bound to one of the aromatic rings of the macrocyclic composition via a reactive functional group.
- the targeting composition is represented by Formula (II)
- a ⁇ A 10 , M, L 1 , L 2 , r, and s have the same meanings provided provided for any embodiment herein with the exception that at least one of the R groups (R ⁇ R 10 ) is or includes a selective cancer cell targeting group, which may be any one or more of the selective cancer cell targeting groups provided above including a particle containing such groups.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 is a selective cancer cell targeting group or a selective cancer cell targeting group linked to the carbon atom to which it is attached by a alkylene, -0-, -S-, -(OCH 2 CH 2 ) z - (where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -C(O)-, -OC(O)-, - C(0)0-, -C(S)0-, -C(0)NR'-, -C(S)NR', -NR'C(O)-, -NR'C(S)-, -NR'-, -NR'C(0)N-, - NR'C(S)N-, -S(O)-, -S0 2 -, -S(0) 2 0-, -S0 2 NR'-, -P(0)(OR'
- Formula (II) includes the same number of sub-generic structures under Formula (I), except that at least one of the R groups (R ⁇ R 10 ) is or includes a selective cancer cell targeting group.
- An analogous series of sub-generic structures under Formula (II) are derived from Formulas (I-a) to (I-x) by requiring at least one of the R groups (R ⁇ R 10 ) in each of these sub-generic formulas to include a selective cancer cell targeting group.
- the sub-generic structures under Formula (II) can thus be identified as Formulas (Il-a) to (II-x), in analogy to Formulas (Il-a) to (II-x).
- compositions according to Formula (I) and Formula (II) are provided.
- aromatic rings can be attached to the macrocyclic portion by methods well known in the art to produce a ligand moiety, which corresponds to the structure shown in Formula (I) or Formula (II), except without the alpha-emitting radionuclide M.
- the ligand is then complexed with the radionuclide by methods well known in the art.
- Functional groups such as any of those provided for R ⁇ -R 10 , are typically present on the aromatic rings, often in protected form, when the aromatic rings are being attached to the macrocyclic portion; however, in some cases, the aromatic rings may be attached to the macrocyclic portion before being functionalized with any of the functional groups provided for R 1 -R 10 .
- a composition under Formula (I) containing at least one reactive functional group is reacted with a selective cancer cell targeting group to bind the selective cancer cell targeting group, via the reactive functional group, to the aromatic ring attached to the macrocyclic portion.
- an isocyanate or isothiocyanate reactive functional group can be included on at least one aromatic ring of the composition in Formula (I), and the resulting functionalized composition appended to an amino acid-containing targeting agent by reaction of the isocyanate or isothiocyanate group with amino groups in the amino acid-containing targeting agent to produce a targeting composition of Formula (II).
- the amino-containing targeting agent becomes bound to the macrocyclic complex by a urea or thiourea linkage. Numerous other modes of attachment, with different linkages, are possible depending on the reactive functional group used.
- the attachment of the selective cancer cell targeting group may be performed on the uncomplexed or complexed form of Formula (I).
- the uncomplexed form of Formula (I) can be complexed with a radionuclide at room temperature (generally 18-30°C, or about or no more than 20°C, 25°C, or 30°C) at high radiochemical yields, e.g., at least or greater than 90%, 95%, 97%, or 98%.
- a radionuclide at room temperature generally 18-30°C, or about or no more than 20°C, 25°C, or 30°C
- high radiochemical yields e.g., at least or greater than 90%, 95%, 97%, or 98%.
- the targeting composition according to Formula (II) contains a targeting agent, as attached by reaction of the reactive functional group with the targeting agent, the target composition according to Formula (II) generally does not include substantially reactive functional groups, such as those used for attaching the targeting agent in the first place.
- the targeting composition according to Formula (II) may include any of the groups listed for R ⁇ R 10 under Formula (I), except the reactive functional groups found in the second set functional groups.
- compositions ⁇ e.g., pharmaceutical compositions
- medicaments comprising any of one of the embodiments of the compounds of Formula II (or a pharmaceutically acceptable salt thereof) disclosed herein and a pharmaceutically acceptable carrier or one or more excipients or fillers (collectively refered to as
- compositions may be used in the methods and treatments described herein.
- the pharmaceutical composition may include an effective amount of any of one of the embodiments of the compounds of the present technology disclosed herein. In any of the above embodiments, the effective amount may be determined in relation to a subject. "Effective amount” refers to the amount of a compound or composition required to produce a desired effect.
- One non-limiting example of an effective amount includes amounts or dosages that yield acceptable toxicity and bioavailability levels for therapeutic (pharmaceutical) use including, but not limited to, the treatment of e.g., prostate cancer, breast cancer, or bladder cancer.
- an effective amount includes amounts or dosages that are capable of reducing symptoms associated with e.g., prostate cancer, breast cancer, or bladder cancer., such as, for example, reduction in proliferation and/or metastasis of prostate cancer, breast cancer, or bladder cancer.
- the effective amount may be from about 0.01 ⁇ g to about 1 mg of the compound per gram of the composition, and preferably from about 0.1 ⁇ g to about 500 ⁇ g of the compound per gram of the composition.
- a "subject" or “patient” is a mammal, such as a cat, dog, rodent or primate.
- the subject is a human, and, preferably, a human suffering from or suspected of suffering from non- small cell lung cancer, bladder cancer, or colon cancer (such as colon adenocarcinoma).
- a human suffering from or suspected of suffering from non- small cell lung cancer, bladder cancer, or colon cancer such as colon adenocarcinoma.
- colon cancer such as colon adenocarcinoma.
- a unit dosage including a compound of the present technology will vary depending on patient considerations. Such considerations include, for example, age, protocol, condition, sex, extent of disease, contraindications, concomitant therapies and the like. An exemplary unit dosage based on these considerations may also be adjusted or modified by a physician skilled in the art. For example, a unit dosage for a patient comprising a compound of the present technology may vary from 1 x 10 ⁇ 4 g/kg to 1 g/kg, preferably, 1 x 10 ⁇ 3 g/kg to 1.0 g/kg.
- Dosage of a compound of the present technology may also vary from 0.01 mg/kg to 100 mg/kg or, preferably, from 0.1 mg/kg to 10 mg/kg.
- Suitable unit dosage forms include, but are not limited to powders, tablets, pills, capsules, lozenges, suppositories, patches, nasal sprays, injectibles, implantable sustained-release formulations, rnucoadherent films, topical varnishes, lipid complexes, etc.
- compositions may be prepared by mixing one or more compounds of Formulas II, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, or solvates thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like to prevent and treat disorders associated with cancer (e.g., prostate cancer, breast cancer, or bladder cancer).
- cancer e.g., prostate cancer, breast cancer, or bladder cancer.
- the compounds and compositions described herein may be used to prepare formulations and medicaments that treat e.g., prostate cancer, breast cancer, or bladder cancer.
- Such compositions may be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
- compositions may be formulated for various routes of administration, for example, by oral, parenteral, topical, rectal, nasal, vaginal administration, or via implanted reservoir.
- Parenteral or systemic administration includes, but is not limited to, subcutaneous, intravenous, intraperitoneal, and intramuscular, injections.
- the following dosage forms are given by way of example and should not be construed as limiting the instant present technology.
- powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant present technology, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive such as a starch or other additive.
- Suitable additives are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides.
- oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets and pills may be further treated with suitable coating materials known in the art.
- suitable coating materials known in the art.
- Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may contain an inactive diluent, such as water.
- Pharmaceutical formulations and medicaments may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
- Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
- suspensions may include oils.
- oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
- Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
- Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
- Ethers such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
- Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Typically, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
- the pharmaceutical formulation and/or medicament may be a powder suitable for reconstitution with an appropriate solution as described above.
- these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
- the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- Compounds of the present technology may be administered to the lungs by inhalation through the nose or mouth.
- suitable pharmaceutical formulations for inhalation include solutions, sprays, dry powders, or aerosols containing any appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
- Aqueous and nonaqueous (e.g., in a fluorocarbon propellant) aerosols are typically used for delivery of compounds of the present technology by inhalation.
- compositions may also include, for example, micelles or liposomes, or some other encapsulated form.
- Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant present technology.
- test subjects will exhibit a 10%, 20%, 30%, 50% or greater reduction, up to a 75-90%, or 95% or greater, reduction, in one or more symptom(s) caused by, or associated with, the disorder in the subject, compared to placebo-treated or other suitable control subjects.
- the present technology provides a method of treating cancer by administering an effective amount of the targeting composition according to Formula (II) to a subject having cancer.
- a cancer cell targeting agent can be selected to target any of a wide variety of cancers, the cancer considered herein for treatment is not limited.
- the cancer can be essentially any type of cancer.
- antibodies or peptide vectors can be produced to target any of a wide variety of cancers.
- the targeting compositions described herein are typically administered by injection into the bloodstream, but other modes of administration, such as oral or topical administration, are also considered.
- the targeting composition may be administered locally, at the site where the target cells are present, i.e., in a specific tissue, organ, or fluid ⁇ e.g., blood, cerebrospinal fluid, etc.).
- a specific tissue, organ, or fluid e.g., blood, cerebrospinal fluid, etc.
- Any cancer that can be targeted through the bloodstream is of particular consideration herein.
- Some examples of applicable body parts containing cancer cells include the breasts, lungs, stomach, intestines, prostate, ovaries, cervix, pancreas, kidney, liver, skin, lymphs, bones, bladder, uterus, colon, rectum, and brain.
- the cancer can also include the presence of one or more carcinomas, sarcomas, lymphomas, blastomas, or teratomas (germ cell tumors).
- the cancer may also be a form of leukemia.
- the cancer is a triple negative breast cancer.
- the dosage of the active ingredient(s) generally depends on the disorder or condition being treated, the extent of the disorder or condition, the method of administration, size of the patient, and potential side effects.
- a suitable dosage of the targeting composition may be precisely, at least, above, up to, or less than, for example, 1 mg, 10 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1200 mg, or 1500 mg, or a dosage within a range bounded by any of the foregoing exemplary dosages.
- composition can be administered in the indicated amount by any suitable schedule, e.g., once, twice, or three times a day or on alternate days for a total treatment time of one, two, three, four, or five days, or one, two, three, or four weeks, or one, two, three, four, five, or six months, or within a time frame therebetween.
- schedule e.g., once, twice, or three times a day or on alternate days for a total treatment time of one, two, three, four, or five days, or one, two, three, or four weeks, or one, two, three, four, five, or six months, or within a time frame therebetween.
- the composition can be administered until a desired change in the disorder or condition is realized, or when a preventative effect is believed to be provided.
- HPLC system used for analysis and purification of compounds consisted of a CBM-20A communications bus module, an LC-20AP (preparative) or LC-20AT (analytical) pump, and an SPD-20AV UV/Vis detector monitoring at 270 nm
- Method B 10% C (0-5 min), 10-100% C (5-25 min).
- Method C 10% C (0-5 min), 10-100% C (5-40 min).
- Method D 10% C (0-5 min), 10-100% C (5-20 min).
- the solvent systems contained 0.1% trifluoroacetic acid (TFA), except for Method C, in which 0.2% TFA was used.
- MR spectra were recorded at ambient temperature on Varian Inova 300 MHz, 400 MHz, 500 MHz or 600 MHz spectrometers, or on a Bruker AV III HD 500 MHz spectrometer equipped with a broadband Prodigy cryoprobe. Chemical shifts are reported in ppm.
- IR spectroscopy was performed on a KBr pellet of sample using a Nicolet Avatar 370 DTGS (ThermoFisher Scientific, Waltham, MA).
- HRMS High-resolution mass spectra
- UV/visible spectra were recorded on a Cary 8454 UV-Vis (Agilent Technologies, Santa Clara, CA) using 1-cm quartz cuvettes, unless otherwise noted.
- Elemental analysis (EA) was performed by Atlantic Microlab, Inc. (Norcross, GA).
- Hydrogen atoms were included in the model at geometrically calculated positions and refined using a riding model. Hydrogen atoms bound to nitrogen and oxygen were located in the difference Fourier synthesis and subsequently refined semi-freely with the help of distance restraints. The isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups). For
- La 3+ and Lu 3+ Titrations with Macropa The pH of a 10 mM 3-(N- morpholino)propanesulfonic acid (MOPS) buffer was adjusted to 7.4 using aqueous Me 4 OH. The ionic strength was set at 100 mM using Me 4 Cl.
- Stock solutions of LaCl 3 6.8H 2 0 (40 mM) and LuCl 3 6H 2 0 (21 mM) were prepared in 1 mM HC1.
- H 2 macropa-2HCl-4H 2 0 (8.8 mM) was prepared in MOPS buffer. From these stock solutions, titration solutions containing macropa (100 ⁇ ) and either LaCl 3 or LuCl 3 were prepared in MOPS. Each metal ion titration was carried out at RT by adding 5-10 ⁇ _, aliquots of titrant to a cuvette containing 3000 ⁇ _, of macropa (100 ⁇ ) in MOPS. Each sample was allowed to equilibrate for 5 min following every addition before a spectrum was acquired. Complexation of the metal ion was monitored by the decrease in absorbance at 268 nm, the Xm ax of macropa. Titrant was added until no further spectral changes were detected.
- a stock solution of ethylenediaminetetraacetic acid (EDTA, 100 mM) was made in MOPS buffer (prepared as described above) by adjusting the pH of the initial suspension to 6.6 using aqueous Me 4 OH.
- a stock solution of diethylenetriaminepentaacetic acid (DTP A, 125 mM) was prepared in H 2 0 by adjusting the pH to 7.4 as described for EDTA. This solution was serially diluted with H 2 0 to yield 12.5 mM and 1.25 mM solutions of DTPA.
- TLC plates Aluminum-backed TLC plates (silica gel 60, F 2 54, EMD Millipore, Darmstadt, Germany) were used to analyze 225 Ac radiolabeling reaction progress.
- Instant thin layer chromatography paper impregnated with silica gel iTLC- SG, Agilent Technologies, Mississauga, ON, Canada
- TLC plates were developed and then counted on a BioScan System 200 imaging scanner equipped with a BioScan Autochanger 1000 and WinScan software at least 8 h later to allow time for daughter isotopes to decay completely, ensuring that the radioactive signal
- ligand (10 ⁇ .) and 225 Ac (10-26 kBq, 10-30 pL) were sequentially added to H 4 OAc buffer (pH 6, 0.15 M, 150 ⁇ ) to give final ligand concentrations of 5.3 x 10 ⁇ 5 -5.9 x 10 ⁇ 10 M for macropa and 5.9 x 10 ⁇ 5 - 5.9 x 10 ⁇ 9 M for DOTA.
- the final pH of all labeling reactions was between 5.5 and 6.
- the reaction solutions were maintained at ambient temperature or 80 °C. Reaction progress was monitored at 5 and 30 min by spotting 3-5 ⁇ . of the reaction solution onto TLC plates. The plates were developed with a mobile phase of 0.4 M sodium citrate (pH 4) containing 10%
- Macropa 100 ⁇ L of a lmg/mL solution in H 4 OAc was diluted with 387 ⁇ L of H 4 OAc (1 M, pH 7), and an aliquot (203 L) of 225 Ac(N0 3 ) 3 (-157 kBq) was then added; the pH of this solution was adjusted to 6.5-7 by the addition of 1 M NaOH (210 ⁇ ., trace metal grade).
- the reaction solution was analyzed by TLC (0.4 M pH 4 sodium citrate as the eluent), which confirmed >95% radiochemical yield. The reaction was allowed to proceed overnight, and the radiochemical yield was again confirmed to be >95% the following morning. At this time, mice were anesthetized by 2% isoflurane, and
- Tissues were weighed and then counted with a calibrated gamma counter (Packard, Cobra II model 5002) using three energy windows: 60-120 keV (window A), 180-260 keV (window B), and 400-480 keV (window C). Counting was performed both immediately after sacrifice and after 7 days; counts were decay corrected from the time of injection and then converted to the percentage of injected dose (% ID) per gram of tissue (% ID/g). No differences were noted between the data; therefore, the biodistributions are reported using the data acquired
- 225 225 described above for [ Ac(macropa)] with the following modifications.
- [ Ac(DOTA) was prepared by adding 225 Ac(N0 3 ) 3 (338 L, 1.1 MBq) to a solution of DOTA (100 ⁇ g, 20 mg/mL in H 2 0) in NH 4 OAc (467 ⁇ ⁇ , 0.15 M, pH 7). The pH of the solution was adjusted to 7 using H 4 OAc (150 uL, 1 M, pH 7) and the solution was heated at 85 °C for 45 min. RCY > 99% was confirmed by TLC as described above.
- [ 225 Ac(DOTA)] ⁇ was diluted with saline to a final concentration of 0.05 MBq/100 pL, and 100 ⁇ L ⁇ were injected into each mouse.
- 225 Ac(N0 3 ) 3 (-58 pL, 0.4 MBq) was diluted and injected in the same manner as [ 225 Ac(DOTA)]-.
- Method D was employed for macropa-NCS.
- Method B was employed for /?-SCN-Bn-DOTA using an Epic Polar C18 column, 120 A, 10 ⁇ , 25 cm x 4.6 mm (ES Industries, West Berlin, NJ) at a flow rate of 1 mL/min. Between samplings, the vials were stored at room temperature (23 ⁇ 1 °C) away from light. Hydrolysis was considered complete once the peak at 13.8 min (corresponding to 12) or 18.417 min (corresponding to /?-SCN-Bn-DOTA) had disappeared or had negligible integration.
- a linear regression performed on the plots of In peak area versus time provided the pseudo-first order rate constant (& 0bS ) as the negative slope.
- DTP A diethylenetriaminepentaacetic acid
- MOPS buffer pH 7.4
- a MOPS solution containing macropa-NHC(S)NHCH 3 (126.7 ⁇ , 16.7%) ACN by volume) and LaCl 3 (126.2 ⁇ ) was prepared using the stock solutions described above and was left to equilibrate for 10 min. Subsequently, it was portioned into cuvettes and diluted with either 125 mM DTP A, 12.5 mM DTP A, or MOPS to yield solutions containing 1000-, 100-, or 0-fold excess DTP A.
- the final concentration of macropa- HC(S) HCH 3 in each cuvette was 25.3 ⁇ .
- These solutions were repeatedly analyzed by UV spectrophotometry over the course of 21 days for any spectral changes. The final pH of each solution was between 7.42 and 7.49. The experiment was performed in triplicate.
- the concentration of purified Tmab was calculated via the Beer-Lambert law using A 280 and an ⁇ 28 ⁇ of 1.446 mL mg "1 cm "1 .' 1071 Purified Tmab and Tmab conjugates were stored at 4 °C.
- Macropa-NCS was estimated to be in 16-fold molar excess to Tmab based on a molecular weight of 1045.76 g/mol for 12 (tetra-TFA salt).
- the pH of this solution was between 8 and 9 by litmus paper. The solution was rocked gently at room temperature for 17.5 h and then purified using a spin column.
- 225 Ac Radiolabeling Studies In a total reaction volume of 200 ⁇ L made up with NH 4 OAc buffer (pH 6, 0.15 M), 225 Ac (10 or 20 kBq, 7-10 uL) was mixed with 25-100 ⁇ g of either macropa-Tmab (5.5-22 ⁇ ) or DOTA-Tmab (8.81-35.2 ⁇ L), and the pH was adjusted to ⁇ 5 with NaOH. A control solution was also prepared in which unmodified Tmab (25 ⁇ g) was substituted in place of conjugate. The reaction solutions were maintained at ambient
- Radium-223 ( 223 Ra) is the first therapeutic alpha (a)-emitting radionuclide to be approved for clinical use in cancer patients, and is effective in erradicating bone metastases.
- TAT targeted alpha-particle therapy
- Actinium-225 ( 225 Ac) was examined for use in TAT owing to its long 10-day half-life that is compatible with antibody -based targeting vectors and 4 high-energy a-emissions that are extremely lethal to cells.
- the 12-membered tetraaza macrocycle H 4 DOTA is currently the state of the art for the chelation of the 225 Ac 3+ ion, however, the thermodynamic stabilities of complexes of H 4 DOTA decrease as the ionic radius of the metal ion increases, indicating that this ligand is not optimal for chelation of the of the Ac 3+ ion (the largest +3 ion on the periodic table).
- the macrocyclic complexes of the present technology provide a signifiant and unexpected improvement over known complexes, where the present examples (H 2 macropa and H 2 macropa-NCS; Scheme 1) illustrate the improved 225 Ac bifunctional chelators according to the present technology.
- the La 3+ and Lu 3+ complexes of macropa were isolated and their solid-state structures were elucidated by X-ray crystallography (FIGS. 1A-1D).
- the La 3+ and Lu 3+ ions reside above the 18-membered macrocycle, and the two picolinate arms are positioned on the same side of the macrocycle.
- the coordination sphere of the Lu 3+ ion is satisfied by the ten donors of macropa with both picolinate arms deprotonated; by contrast, the larger La 3+ ion forms an 11 -coordinate complex by the incorporation of an inner-sphere water molecule that penetrates the macrocycle.
- the ability of macropa to form stable 11 -coordinate complexes is of particular significance because recent EXAFS studies have demonstrated that Ac 3+ prefers a coordination number of 11 in aqueous solutions. [29 ' 30]
- Macropa was examined for the chelation of the larger, radioactive 225 Ac 3+ ion and compared to DOTA. Both ligands (59 ⁇ ) were incubated with 225 Ac (26 kBq) in 0.15 M
- FIG. 2A demonstrates slow blood clearance and excretion, coupled to large accumulation in the liver and spleen of the uncomplexed 225 Ac(N0 3 ) 3 .
- [ 225 Ac(macropa)] + (FIG. 3B) differs markedly from that of 225 Ac(N0 3 ) 3 .
- [ 225 Ac(macropa)] + was rapidly cleared from mice, with very little activity measured in blood by 1 h post injection. Most of the injected dose was renally excreted and subsequently detected in the urine, demonstrating the moderate kidney and bladder uptake of [ 225 Ac(macropa)] + observed in mice at 15 min and 1 h post injection. Of significance, [ 225 Ac(macropa)] + did not accumulate in any organ over the time course of the study, indicating that the complex does not release free 225 Ac 3+ in vivo. Its biodistribution profile was similar to that of [ 225 Ac(DOTA)] " (FIG. 3C), which has been previously shown to retain 225 Ac 3 in vivo. ⁇ 1 ⁇ 1 1
- the present technology may include, but is not limited to, the features and
- M is an alpha-emitting radionuclide
- a 1 is N or CR 1 ;
- a 2 is N or CR 2 ;
- a 3 is N or CR 3 ;
- a 4 is N or CR 4 ;
- a 5 is N or CR 5 ;
- a 6 is N or CR 6 ;
- a 7 is N or CR 7 ;
- a 8 is N or CR 8 ;
- a 9 is N or CR 9 :
- a 10 is N or CR 10 ; provided that no more than three of A 1 , A 2 , A 3 , A 4 , and A 5 are N, and no more than three of A 6 , A 7 , A 8 , A 9 , and A 10 are N;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are each independently selected from H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halo, -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', -OC(0)R', -C(0)OR', -C(S)OR', -C(0) R'R', -C(S) R'R',
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 groups are interconnected to form a five- to six-membered substituted or unsubstituted carbocyclic or nitrogen-containing ring;
- R' is independently at each occurance H, Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C5-C5 cycloalkenyl, C 2 -C 6 alkynyl, C5-C5 aryl, heterocyclyl, or heteroaryl, or wherein two R' groups attached to the same atom are interconnected to form a three- to six-membered ring,
- L 1 and L 2 are each independently selected from -(CH 2 ) / ,-, where p is a value of 1, 2, or 3;
- r is 0 or 1
- s is 0 or 1.
- composition of Paragraph A wherein at least one of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 , and A 10 is N.
- composition of Paragraph A or Paragraph B wherein at least one of A 1 , A 2 , A 3 , A 4 , and A 5 is N and at least one of A 6 , A 7 , A 8 , A 9 , and A 10 is N.
- D The composition of Paragraph A or Paragraph B, wherein A 1 , A 2 , A 3 , A 4 , and A 5 are not N.
- Formula I is a composition of Formula I-a
- composition of any one of Paragraphs A-K, wherein one or two pairs of directly adjacent groups among R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 groups are
- R u , R 12 , R 13 , R 14 , R 15 , and R 16 are each independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, halo, -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), - (OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', - OC(0)R', -C(0)OR', -C(S)OR', -C(0) R'R', -C(S) R'R', - R'C(0)R', - R'C(0)R', - R'C(0)R', - R'C(0)R', - R'C(0)R', - R'C(0)R', - R'C(0)R',
- R 11 , R 12 , R 13 , R 14 , R 17 , R 18 , R 19 , and R 20 are each independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, halo, -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', -OC(0)R', -C(0)OR', -C(S)OR', -C(0) R'R', -C(S) R'R',
- R' is independently at each occurence H, Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, Cs-C 6 cycloalkenyl, C 2 -C 6 alkynyl, C 5 -C 6 aryl,
- 225 225 Ac 3+ ), radium-223 ( 233 Ra 2+ ), bismuth-213 ( 213 Bi 3+ ), lead-212 ( 212 Pb 2+ and/or 2 12 Pb 4+ ), terbium-149 ( 149 Tb 3+ ), fermium-255 ( 255 Fm 3+ ), thorium-227 ( 227 Th 4+ ), thorium-
- composition useful in targeted radiotherapy of cancer wherein the composition is of Formula II
- M is an alpha-emitting radionuclide
- a 1 is N or CR 1 ;
- a 2 is N or CR 2 ;
- a 3 is N or CR 3 ;
- a 4 is N or CR 4 ;
- a 5 is N or CR 5 ;
- a 6 is N or CR 6 ;
- a 7 is N or CR 7 ;
- a 8 is N or CR 8 ;
- a 9 is N or CR 9 ;
- a 10 is N or CR 10 ; provided that no more than three of A 1 , A 2 , A 3 , A 4 , and A 5 are N, and no more than three of A 6 , A 7 , A 8 , A 9 , and A 10 are N; at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 is a selective cancer cell targeting group or a selective cancer cell targeting group linked to the carbon atom to which it is attached by a alkylene, -0-, -(OCH 2 CH 2 ) z - (where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -S-, -C(O)-,
- -P(0)(OR')-, -P(0)(R')-, -C(NR')-, -OC(NR')-, -SC(NR')- are each independently linked to the carbon atom to which it is attached by a C1-C3 alkylene;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are each independently selected from H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halo, -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 ) OR' (where;/ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', -OC(0)R', -C(0)OR', -C(S)OR', -C(0)NR'R', - C(S)NR'R', -NR'C(0)R', -NR'C(S)R', -NR'R', -NR'C(0)NR', - NR'C(0)NR',
- R' is independently at each occurance H, Ci-C 6 alkyl, C3-C6 cycloalkyl, C 2 -C 6 alkenyl, Cs-C 6 cycloalkenyl, C 2 -C 6 alkynyl, Cs-C 6 aryl, heterocyclyl, or heteroaryl, or wherein two R' groups attached to the same atom are interconnected to form a three- to six-membered ring,
- L 1 and L 2 are each independently selected from -(CH 2 ) P -, where p is a value of 1, 2, or 3;
- r is 0 or 1
- s is 0 or 1.
- composition of Paragraph Q or Paragraph R, wherein said selective cancer cell targeting group is a cancer-targeting antibody or antibody fragment.
- composition of Paragraph Q or Paragraph R, wherein said selective cancer cell targeting group is an oligopeptide containing up to 50 amino acids.
- a method of treating cancer in a subject comprising administering to a subject having cancer an effective amount of a composition of Formula II
- M is an alpha-emitting radionuclide
- a 1 is N or CR 1 ;
- a 2 is N or CR 2 ;
- a 3 is N or CR 3 ;
- a 4 is N or CR 4 ;
- a 5 is N or CR 5 ;
- a 6 is N or CR 6 ;
- a 7 is N or CR 7 ;
- a 8 is N or CR 8 ;
- a 9 is N or CR 9 ;
- a 10 is N or CR 10 ; provided that no more than three of A 1 , A 2 , A 3 , A 4 , and A 5 are N, and no more than three of A 6 , A 7 , A 8 , A 9 , and A 10 are N; at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 is a selective cancer cell targeting group or a selective cancer cell targeting group linked to the carbon atom to which it is attached by a alkylene, -0-, -(OCH 2 CH 2 ) z -, -S-, -C(O)-, -OC(O)-, -C(0)0-, -C(S)0-, -C(0) R'-, -C(S) R', - R'C(O)-, - R'C(S)-, -NR'-, - R'C(0)N-, - R'
- -P(0)(OR')-, -P(0)(R')-, -C(NR')-, -OC(NR')-, -SC(NR')- are each independently linked to the carbon atom to which it is attached by a C1-C3 alkylene;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are each independently selected from H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halo, -OR', -(OCH 2 CH 2 ) x -R' (where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -(OCH 2 CH 2 VOR' (where .y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), -SR', -OC(0)R', -C(0)OR', -C(S)OR', -C(0) R'R',
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 groups are interconnected to form a five- to six-membered substituted or unsubstituted carbocyclic or nitrogen-containing ring;
- R' is independently at each occurance H, Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C5-C5 cycloalkenyl, C 2 -C 6 alkynyl, C5-C5 aryl, heterocyclyl, or heteroaryl, or wherein two R' groups attached to the same atom are interconnected to form a three- to six-membered ring,
- L 1 and L 2 are each independently selected from -(CH 2 ) / ,-, where p is a value of 1, 2, or 3;
- r is 0 or 1
- s is 0 or 1.
- M is selected from actinium-225 ( 225 Ac 3+ ), radium-223 ( 233 Ra 2+ ), bismuth- 213 ( 213 Bi 3+ ), lead-212 ( 212 Pb 2+ and/or 212 Pb 4+ ), terbium-149
- composition comprising a pharmaceutically acceptable carrier and a composition of any one of Paragraphs A-T.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478945P | 2017-03-30 | 2017-03-30 | |
PCT/US2018/025488 WO2018183906A1 (en) | 2017-03-30 | 2018-03-30 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3600452A1 true EP3600452A1 (en) | 2020-02-05 |
EP3600452A4 EP3600452A4 (en) | 2020-11-18 |
EP3600452B1 EP3600452B1 (en) | 2024-09-04 |
Family
ID=63676871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18775715.8A Active EP3600452B1 (en) | 2017-03-30 | 2018-03-30 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
Country Status (9)
Country | Link |
---|---|
US (2) | US11554182B2 (en) |
EP (1) | EP3600452B1 (en) |
JP (1) | JP2020515596A (en) |
KR (2) | KR102670305B1 (en) |
CN (1) | CN110573186A (en) |
AU (1) | AU2018243682B2 (en) |
CA (1) | CA3058454A1 (en) |
IL (2) | IL269763B2 (en) |
WO (1) | WO2018183906A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020180756A1 (en) * | 2019-03-01 | 2020-09-10 | Washington University | Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade |
MX2021013667A (en) | 2019-05-10 | 2022-01-31 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof. |
EP4243935A1 (en) | 2020-11-10 | 2023-09-20 | Janssen Biotech, Inc. | Macrocyclic compounds and methods of use thereof |
EP4284446A2 (en) | 2021-01-27 | 2023-12-06 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
TW202241526A (en) * | 2021-02-01 | 2022-11-01 | 德商拜耳廠股份有限公司 | Multimeric chelator compounds for use in targeted radiotherapy |
JP2024045789A (en) * | 2021-02-19 | 2024-04-03 | 住友化学株式会社 | Compound and metal complex |
JP2024060110A (en) * | 2021-02-19 | 2024-05-02 | 住友化学株式会社 | Radioactive metal complex and method for producing the same |
KR20240014479A (en) | 2021-05-27 | 2024-02-01 | 얀센 바이오테크 인코포레이티드 | Compositions and methods for treating prostate cancer |
EP4392081A1 (en) * | 2021-08-27 | 2024-07-03 | Janssen Biotech, Inc. | Anti-psma radioconjugates and uses thereof |
IL311070A (en) | 2021-08-27 | 2024-04-01 | Janssen Biotech Inc | Anti-psma antibodies and uses thereof |
EP4429718A1 (en) | 2021-11-09 | 2024-09-18 | Janssen Biotech, Inc. | Macrocyclic compounds and diagnostic uses thereof |
CA3240194A1 (en) | 2021-11-09 | 2023-05-19 | Edward Cleator | Macrocyclic compounds and methods of making the same |
CN118613288A (en) | 2022-01-26 | 2024-09-06 | 詹森生物科技公司 | Immunoconjugates comprising kallikrein-related peptidase 2 antigen binding domains and uses thereof |
WO2023215293A1 (en) | 2022-05-02 | 2023-11-09 | Athanor Biosciences, Inc. | Cancer eradicating – bio-nanoparticles (ce-bnp) |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
EP4279092A1 (en) | 2022-05-17 | 2023-11-22 | Bayer AG | Radiopharmaceutical complexes targeting prostate-specific membrane antigen |
WO2023222557A1 (en) | 2022-05-17 | 2023-11-23 | Bayer Aktiengesellschaft | Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4597903A (en) * | 1984-08-21 | 1986-07-01 | University Of Maryland | Process for the direct preparation of N,N-disubstituted derivatives for 4,13-diaza-18-crown-6 |
US5747345A (en) * | 1996-08-15 | 1998-05-05 | Johnson & Johnson Clinical Diagnostics, Inc. | Calcium specific diaza-18-crown-6-ether chromoionophores |
JP2002098981A (en) * | 2000-09-21 | 2002-04-05 | Seiko Epson Corp | Liquid crystal device and method for manufacturing the same, and electronic device |
GB0624587D0 (en) * | 2006-12-08 | 2007-01-17 | Univ Muenchen Tech | Chelating agent |
ES2354666B1 (en) * | 2009-07-27 | 2012-01-03 | Universidade Da Coruña Y En Su Nombre Y Representacion El Rector Jose Maria Barja Perez | COMPOSITE FOR SELECTIVE EXTRACTION OF STRONTIUM (II) AND LEAD (II). |
CN103421133A (en) * | 2013-08-03 | 2013-12-04 | 大连理工大学 | Rare-earth metal catalysis system for catalyzing high-stereoregularity polymerization of alpha-olefin |
WO2015176056A1 (en) * | 2014-05-16 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | One-step labeling of antibodies to high specific activity with actinium-225 |
MA41176A (en) | 2014-12-17 | 2017-10-24 | Bayer As | RADIO-PHARMACEUTICAL COMPLEXES |
US10806806B2 (en) * | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
-
2018
- 2018-03-30 US US16/499,070 patent/US11554182B2/en active Active
- 2018-03-30 CN CN201880025643.8A patent/CN110573186A/en active Pending
- 2018-03-30 IL IL269763A patent/IL269763B2/en unknown
- 2018-03-30 IL IL311111A patent/IL311111A/en unknown
- 2018-03-30 JP JP2019553433A patent/JP2020515596A/en active Pending
- 2018-03-30 AU AU2018243682A patent/AU2018243682B2/en active Active
- 2018-03-30 CA CA3058454A patent/CA3058454A1/en active Pending
- 2018-03-30 KR KR1020197029951A patent/KR102670305B1/en active IP Right Grant
- 2018-03-30 WO PCT/US2018/025488 patent/WO2018183906A1/en unknown
- 2018-03-30 EP EP18775715.8A patent/EP3600452B1/en active Active
- 2018-03-30 KR KR1020247017348A patent/KR20240093912A/en not_active Application Discontinuation
-
2022
- 2022-12-19 US US18/084,480 patent/US20230372550A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL269763A (en) | 2019-11-28 |
IL269763B2 (en) | 2024-08-01 |
WO2018183906A1 (en) | 2018-10-04 |
IL269763B1 (en) | 2024-04-01 |
US11554182B2 (en) | 2023-01-17 |
US20230372550A1 (en) | 2023-11-23 |
KR102670305B1 (en) | 2024-05-30 |
EP3600452A4 (en) | 2020-11-18 |
EP3600452B1 (en) | 2024-09-04 |
JP2020515596A (en) | 2020-05-28 |
CN110573186A (en) | 2019-12-13 |
KR20240093912A (en) | 2024-06-24 |
CA3058454A1 (en) | 2018-10-04 |
IL311111A (en) | 2024-04-01 |
AU2018243682B2 (en) | 2023-11-09 |
AU2018243682A1 (en) | 2019-10-17 |
US20210085808A1 (en) | 2021-03-25 |
KR20190139222A (en) | 2019-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018243682B2 (en) | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | |
US11279698B2 (en) | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | |
US20230114130A1 (en) | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | |
US20200405888A1 (en) | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | |
WO2022251516A2 (en) | Complexes with acyclic chelators and their use in targeted radiotherapy of cancer | |
WO2022251541A1 (en) | Macrocycles and complexes with radionuclides useful in targeted radiotherapy of cancer | |
NZ789339A (en) | Double targeting constructs to affect tumor kill |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191007 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602018073993 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0051000000 Ipc: A61K0051040000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0051000000 Ipc: A61K0051040000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201016 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 51/10 20060101ALI20201012BHEP Ipc: A61M 36/14 20060101ALI20201012BHEP Ipc: A61P 35/00 20060101ALI20201012BHEP Ipc: A61K 51/04 20060101AFI20201012BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210621 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240402 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CORNELL UNIVERSITY |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Free format text: CASE NUMBER: APP_44689/2024 Effective date: 20240801 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |